个体患者数据荟萃分析确定磁共振弹性成像对NAFLD纤维化分期的截断值及混杂因素
该个体患者数据荟萃分析纳入8个独立队列共798例NAFLD患者,确定磁共振弹性成像(MRE)诊断显著纤维化、晚期纤维化和肝硬化的截断值分别为3.14 kPa、3.53 kPa和4.45 kPa,对应AUROC分别为0.92、0.92和0.94。组织学脂肪性肝炎伴较高炎症活动度(OR 2.448,95%CI 1.180-5.079,p<0.05)和高GGT浓度(>120U/L)(OR 3.388,95%CI 1.577-7.278,p<0.01)与肝脏硬度升高显著相关,可能影响早期纤维化(F0-F1)分期的准确性。
要点
- MRE诊断显著纤维化截断值3.14 kPa,AUROC 0.92,敏感度79%,特异度89%。
- MRE诊断肝硬化截断值4.45 kPa,AUROC 0.94,敏感度88%,特异度89%。
- 炎症活动度和GGT升高可能高估早期肝纤维化,BMI和脂肪变程度不是混杂因素。
核心结论
- MRE对NAFLD患者显著纤维化、晚期纤维化和肝硬化具有极好的诊断性能。
- 炎症活动度升高和GGT水平升高可能导致早期肝纤维化高估,但BMI或脂肪变程度等人体测量指标不会。
研究设计与样本
- 个体患者数据荟萃分析,系统检索文献识别报告NAFLD患者MRE数据的研究,从通讯作者获取数据。
- 纳入8个独立队列共798例患者,采用两阶段荟萃分析确定各纤维化分期的合并诊断截断值,并使用多水平模型分析影响MRE诊断准确性的潜在混杂因素。
主要发现
- MRE检测显著纤维化的AUROC为0.92(敏感度79%,特异度89%)。
- MRE检测晚期纤维化的AUROC为0.92(敏感度87%,特异度88%)。
- MRE检测肝硬化的AUROC为0.94(敏感度88%,特异度89%)。
- 广义线性混合模型分析显示,组织学脂肪性肝炎伴较高炎症活动度(OR 2.448,95%CI 1.180-5.079,p<0.05)和高GGT浓度(>120U/L)(OR 3.388,95%CI 1.577-7.278,p<0.01)与肝脏硬度升高显著相关,影响早期纤维化(F0-F1)分期的准确性。
- 磁共振成像质子密度脂肪分数测定的脂肪变性和BMI不是混杂因素。
关键数值与推荐
- MRE与组织病理学一致性截断值:≥F2为3.14 kPa(检验前概率39.4%)。
- ≥F3为3.53 kPa(检验前概率24.1%)。
- F4为4.45 kPa(检验前概率8.7%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: We conducted an individual patient data meta-analysis to establish stiffness cut-off values for magnetic resonance elastography (MRE) in staging liver fibrosis and to assess potential confounding factors. METHODS: A systematic review of the literature identified studies reporting MRE data in patients with NAFLD. Data were obtained from the corresponding authors. The pooled diagnostic cut-off value for the various fibrosis stages was determined in a two-stage meta-analysis. Multilevel modelling methods were used to analyse potential confounding factors influencing the diagnostic accuracy of MRE in staging liver fibrosis. RESULTS: Eight independent cohorts comprising 798 patients were included in the meta-analysis. The area under the receiver operating characteristic curve (AUROC) for MRE in detecting significant fibrosis was 0.92 (sensitivity, 79%; specificity, 89%). For advanced fibrosis, the AUROC was 0.92 (sensitivity, 87%; specificity, 88%). For cirrhosis, the AUROC was 0.94 (sensitivity, 88%, specificity, 89%). Cut-offs were defined to explore concordance between MRE and histopathology: ≥F2, 3.14 kPa (pretest probability, 39.4%); ≥F3, 3.53 kPa (pretest probability, 24.1%); and F4, 4.45 kPa (pretest probability, 8.7%). In generalized linear mixed model analysis, histological steatohepatitis with higher inflammatory activity (odds ratio 2.448, 95% CI 1.180-5.079, p <0.05) and high gamma-glutamyl transferase (GGT) concentration (>120U/L) (odds ratio 3.388, 95% CI 1.577-7.278, p <0.01] were significantly associated with elevated liver stiffness, and thus affecting accuracy in staging early fibrosis (F0-F1). Steatosis, as measured by magnetic resonance imaging proton density fat fraction, and body mass index(BMI) were not confounders. CONCLUSIONS: MRE has excellent diagnostic performance for significant, advanced fibrosis and cirrhosis in patients with NAFLD. Elevated inflammatory activity and GGT level may lead to overestimation of early liver fibrosis, but anthropometric measures such as BMI or the degree of steatosis do not. IMPACT AND IMPLICATIONS: This individual patient data meta-analysis of eight international cohorts, including 798 patients, demonstrated that MRE achieves excellent diagnostic accuracy for significant, advanced fibrosis and cirrhosis in patients with NAFLD. Cut-off values (significant fibrosis, 3.14 kPa; advanced fibrosis, 3.53 kPa; and cirrhosis, 4.45 kPa) were established. Elevated inflammatory activity and gamma-glutamyltransferase level may affect the diagnostic accuracy of MRE, leading to overestimation of liver fibrosis in early stages. We observed no impact of diabetes, obesity, or any other metabolic disorder on the diagnostic accuracy of MRE.
引用
- Liang JX, Ampuero J, Niu H, et al. An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography. J Hepatol. 2023. PMID: 37121437. doi:10.1016/j.jhep.2023.04.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。